FY2025 EPS Estimates for VERA Reduced by Cantor Fitzgerald

Vera Therapeutics, Inc. (NASDAQ:VERA) – Investment analysts at Cantor Fitzgerald cut their FY2025 EPS estimates for Vera Therapeutics in a research report issued on Tuesday, March 4th. Cantor Fitzgerald analyst P. Stavropoulos now forecasts that the company will post earnings of ($2.53) per share for the year, down from their prior estimate of ($2.22). The consensus estimate for Vera Therapeutics’ current full-year earnings is ($2.89) per share.

Vera Therapeutics (NASDAQ:VERA) last posted its quarterly earnings data on Wednesday, February 26th. The company reported ($0.72) EPS for the quarter, beating analysts’ consensus estimates of ($0.83) by $0.11.

VERA has been the topic of a number of other reports. Guggenheim boosted their price target on shares of Vera Therapeutics from $59.00 to $61.00 and gave the stock a “buy” rating in a research note on Thursday, February 27th. Wells Fargo & Company began coverage on shares of Vera Therapeutics in a research report on Thursday, November 21st. They set an “overweight” rating and a $70.00 target price on the stock. JPMorgan Chase & Co. lowered their target price on shares of Vera Therapeutics from $77.00 to $71.00 and set an “overweight” rating on the stock in a research report on Tuesday. Wedbush upped their target price on shares of Vera Therapeutics from $30.00 to $38.00 and gave the stock a “neutral” rating in a research report on Friday, November 8th. Finally, Wolfe Research began coverage on shares of Vera Therapeutics in a research report on Tuesday, February 4th. They set an “outperform” rating and a $49.00 target price on the stock. One equities research analyst has rated the stock with a hold rating, six have given a buy rating and three have given a strong buy rating to the company. According to MarketBeat.com, Vera Therapeutics presently has an average rating of “Buy” and a consensus target price of $64.67.

Vera Therapeutics Trading Up 4.8 %

Shares of Vera Therapeutics stock opened at $29.96 on Thursday. Vera Therapeutics has a 52-week low of $25.99 and a 52-week high of $51.61. The company has a quick ratio of 13.76, a current ratio of 13.76 and a debt-to-equity ratio of 0.17. The company’s 50-day simple moving average is $34.97 and its 200-day simple moving average is $40.15. The firm has a market cap of $1.90 billion, a price-to-earnings ratio of -11.48 and a beta of 1.17.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Huntington National Bank acquired a new position in Vera Therapeutics during the 4th quarter worth approximately $26,000. Summit Investment Advisors Inc. lifted its position in shares of Vera Therapeutics by 16.0% during the fourth quarter. Summit Investment Advisors Inc. now owns 4,639 shares of the company’s stock worth $196,000 after purchasing an additional 639 shares in the last quarter. AlphaQuest LLC purchased a new position in shares of Vera Therapeutics in the fourth quarter valued at $34,000. Alliancebernstein L.P. grew its holdings in Vera Therapeutics by 2.0% during the 4th quarter. Alliancebernstein L.P. now owns 40,350 shares of the company’s stock valued at $1,706,000 after purchasing an additional 800 shares in the last quarter. Finally, E Fund Management Co. Ltd. increased its stake in Vera Therapeutics by 22.3% during the 4th quarter. E Fund Management Co. Ltd. now owns 6,203 shares of the company’s stock worth $262,000 after buying an additional 1,130 shares during the period. Institutional investors and hedge funds own 99.21% of the company’s stock.

Insider Buying and Selling

In related news, CEO Marshall Fordyce sold 17,500 shares of the company’s stock in a transaction on Wednesday, January 8th. The shares were sold at an average price of $41.74, for a total transaction of $730,450.00. Following the completion of the sale, the chief executive officer now directly owns 143,603 shares of the company’s stock, valued at approximately $5,993,989.22. This represents a 10.86 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. In the last ninety days, insiders have sold 52,500 shares of company stock valued at $2,305,625. 21.70% of the stock is currently owned by company insiders.

Vera Therapeutics Company Profile

Vera Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial.